Oxford vaccine effective against corona virus, also safe, now reached next phase trial
The results of the first trial on humans of Oxford University’s Corona Virus Vaccine have been published in The Lancet. According to the research paper, antibodies and T-cells were found when the vaccine was given and the side effects were also not serious.
The results of the first trial of Oxford University’s humans in the race for the Corona virus vaccine were published in The Lancet magazine on Monday. The research paper reported that the corona virus vaccine made from the viral vector was resistant to the virus when given ChAdOx1 nCoV-19. It has also been described as safe. Along with this, it has now been made OK for the next phase of trials. Explain that the vaccine of Oxford was being considered ahead of the second vaccine because it gives ‘double protection’ from the virus.
No serious side effects. The research paper reported that the viral vector used in the vaccine contains a spike protein of SARS-CoV-2. In the second phase 1/2, vaccine trials were conducted on people aged 18–55 years at 5 places. In the 56-day trial, between April 23 and May 21, those who were given the vaccine, such as headaches, fever, body ache, complaints were resolved with paracetamol. No more severe side effects occurred.
The paper found in antibodies and T-cells further states that T-cells recognizing spike proteins were observed 14 days later. Antibody (IgG) was also seen to fight these proteins on day 28, which increased when the second dose was given. Antibodies that act on the virus were found after the first dose in 90% of people. On the second dose, the activity of neutralizing antibodies was observed in all volunteers. Together, these two give protection to the body. Actually, earlier studies have revealed that antibodies can also be gone in a few months, but T-cells remain in the body for years.
Safe for the next step. In addition, it has been stated that the results of ChAdOx1 nCoV-19 are in accordance with safety standards and are also causing antibodies response. These results, together with the humoral and cellular response, support this vaccine as a candidate for large-scale third-phase trials. The Oxford team is working on this vaccine together with UK pharmaceutical company AstraZeneca. Astrazeneca is preparing an international supply chain for the vaccine.
Moderna’s results were also successful. Earlier, the American company Moderna’s Corona virus vaccine was fully successful in its first trial. A study published in the New England Journal of Medicine stated that the first test of this vaccine on 45 healthy people has had very good results. This vaccine developed antibodies for corrosion from corona within each individual. This first test included 45 such people who were healthy and their age was between 18 and 55 years.
There are 7 companies in India. In India too, at least seven companies are involved in vaccine making. Talking about the domestic pharma companies, Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotech, Indian Immunologics, Maynavax and Biologics are trying to prepare the vaccine for covid-19.